diabetestalk.net

Indian Insulin Market Size

Lupin To Market Eli Lilly's Insulin Analog Product In India

Lupin To Market Eli Lilly's Insulin Analog Product In India

Lupin and Eli Lilly have expanded partnership in India with the Mumbai-based pharma company launching diabetes drug Eglucent, a new brand of Lilly’s rapid-acting insulin analog Lispro, in the country. As per the agreement, Lupin will market and sell Eglucent through its own specialty field force while Eli Lilly will be responsible for manufacturing and import. Lilly will continue to sell Lispro under the brand name Humalog through its existing channels. Lupin had earlier collaborated with Lilly (July 2011) to promote and distribute Lilly’s Huminsulin range of products ... MORE ON MARKETS: Quick Links Continue reading >>

Diabetes Therapeutics Market In India To 2018 - Rapid Uptake Of Dpp-iv Inhibitors, Glp-1 Agonists And Expanding Insulin Segment To Drive Growth

Diabetes Therapeutics Market In India To 2018 - Rapid Uptake Of Dpp-iv Inhibitors, Glp-1 Agonists And Expanding Insulin Segment To Drive Growth

Description GBI Research, the leading business intelligence provider, has released its latest research “Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth”, which provides insights into the India anti-diabetes market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Insights into the diabetes epidemiology, cost of therapy, research and development pipeline and the promising molecules which are anticipated to be launched by 2018 are discussed in the report. The report provides an in-depth analysis type 1 and type 2 diabetes. The report provides an in-depth analysis on oral anti-diabetics agents, insulin products and drivers and barriers that could significantly impact the overall anti-diabetes market during the forecast period. Additionally, it explores the competitive landscape, including benchmarking the top companies in the market and the key issues and trends that are likely to have an impact on the Indian diabetes market during the forecast period. Finally, a key trend analysis for mergers and acquisitions and licensing agreements involving diabetes therapies is also discussed in the report. GBI Research’s analysis revealed that the overall anti-diabetes market in India was worth $680.3m in 2011 and is projected to grow at a CAGR of 11.3% between 2011 and 2018 to reach $1,446m in 2018. High and growing diabetes population in the country, rising obese and geriatric population, and rapid market adoption of drugs from the classes such as Dipeptidyl Peptidase 4 (DPP-4) inhibitors, Glucagon-Like Peptide (GLP)-1, Sodium-Glucose Trans Continue reading >>

Human Insulin Market Growing At 10.29% Cagr To 2019

Human Insulin Market Growing At 10.29% Cagr To 2019

The Global Human Insulin Market 2015-2019 research report considers revenue generated from the sales of various drugs used in the treatment of diabetes to calculate the worldwide market size of human insulin for the study. Complete report on human insulin market spread across 63 pages, talking about 3 major companies and supported with 23 data exhibits is now available at . The key players in the human insulin market are extending their support to academic institutions for R&D of innovative products for diabetes care. For instance, Sanofi Diabetes collaborated with academic institutions such as Helmholtz Zentrum and Charite to support R&D in the diabetes care segment. The recent collaboration of Sanofi and Gubra to discover new targets for diabetes is based on the consortium between the University of Copenhagen, Gubra and Gentofte Hospital, which is partly funded by the Danish National Advanced Technology foundation. Such collaborations enable the amalgamation of research expertise of academic institutions with the marketing intelligence of pharma companies, which is expected to support the growth of the human insulin market. According to this latest human insulin market report, diabetes is managed by the administration of insulin on a lifelong basis. However, insulin-based therapies are incapable of controlling blood glucose levels completely and are often associated with undesirable effects such as nocturnal hypoglycemia. During the fasting stage, glucose utilization increases and free fatty acid utilization decreases in the muscle cells, leading to hypoglycemia. In addition, fat breakdown decreases and fat storage increases in the liver cells, leading to weight gain. Severe hypoglycemic events and weight gain often result in poor patient compliance. Administered insu Continue reading >>

Lupin Launches Insulin Glargine In India

Lupin Launches Insulin Glargine In India

Indian pharma company, Lupin Limited announced a strategic distribution agreement with LG Life Sciences of South Korea to launch Insulin Glargine, a novel insulin analogue under the brand name Basugine™. According to the agreement, Lupin would be responsible for marketing and sales of Basugine™ in India. The overall diabetes market size within the Indian pharmaceutical market stood at Rs. 6032 Crore growing at 18% (IMS MAT April 2014). The total insulin analogue market size is valued at Rs. 585 Crore with 3 year CAGR of 24%. The total glargine molecule market is Rs. 218.5 Crore with 3 year CAGR of 23%. Lupin ranks 2nd in the conventional insulin market and grew more than the market at 10.82% in April 2014 (IMSD MAT), while the market grew at 8%. Lupin is amongst the fastest growing players in the Oral Anti-Diabetes Drugs market and also in the insulin segment. Insulin Glargine is indicated for once – daily subcutaneous administration for the treatment of adult patients with type 1 diabetes mellitus or in type 2 diabetes mellitus; patients who need basal insulin (long acting) for controlling hyperglycemia. The primary activity of insulin, including Insulin Glargine, is the regulation of glucose metabolism. Insulin and its analogues lower blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Announcing the launch, Mr. Shakti Chakraborty, Group President, India Region Formulations, Lupin said– “I believe that our entry into the insulin analogue market with launch of Basugine is a step in the right direction. Lupin’s foray in this segment will help us furtherstrengthen our Diabetes portfolio enabling us to grow deeperinto the Diabetes segment and will fuel our growth in Continue reading >>

Indian Diabetes Market Report & Outlook For 2010-2015 Through Bharatbook.com

Indian Diabetes Market Report & Outlook For 2010-2015 Through Bharatbook.com

Bharatbook.com announces inclusion of latest report on "Indian Diabetes Market Report & Outlook For 2010-2015"(With around 51 Million diabetes patients, India promises to be amongst the most lucrative diabetes markets in the world. In 2009, the total sales of Insulin and Non-Insulin Anti-diabetics reached US$ 424 Million. Although, this represents just a fraction of the global sales, IMARC expects this market to surge in the future. In 2009, Non-Insulin Anti-diabetics occupied 72% of the total diabetes market. Biguanides represented the leading drug class with a 43% market share. In the next five years, IMARC expects newer classes such as DPP-IV Inhibitors and GLP-1 Agonists to drive the Non-Insulin Anti-diabetics market. From a market share of 6% in 2009, IMARC expects DPP-IV Inhibitors to occupy 17% of the total Non-Insulin Anti-diabetics market by 2015. Unlike Non-Insulin’s, the Insulin market in India was concentrated with the top five players occupying 96% of the total market. The Insulin market is expected to grow at a CAGR of 25% between 2010 and 2015, registering sales worth US$448 Million. During the next five years, the main drivers of this market will be the growth in the total drug treated population coupled with a much improved access and administration of Insulin. Report Highlights * A growing drug treated population coupled with the launch of several new drugs will drive the Indian diabetes market to US$1.4 Billion by 2015. * In 2009, the market for Non-Insulin Anti-diabetics was worth US$ 306 Million. This represented a highly fragmented market with USV being the leading player with a 14% share. * USV’s Glycomet GP (Glimepiride+Metformin) was the leading drug in the Non-Insulin Anti-diabetics market with sales worth nearly US$ 10.5 Million * IMARC ex Continue reading >>

Biosimilar Insulin And Costs

Biosimilar Insulin And Costs

Biosimilars are approved copies of already marketed biological medicines. They provide an alternative to existing biological medicines that have lost their patent protection. The first biosimilar insulin (BioIns) will soon be launched on the EU market (Abasaglar, an insulin glargine developed by Eli Lilly and Boehringer Ingelheim). As the lawsuit with Sanofi has come to an end, this same insulin will be released on the US market soon but under a different name (Basaglar). Interestingly, this insulin was not approved following the new 351(k) biosimilar pathway (see below). It is of note that a major pharmaceutical player (and not a generics or specialty biotech company) has won the race to have the first BioIns approved. An Indian pharmaceutical company tried twice in the past to get approval in the EU, but failed both times.1 From the approval process seen with Abasaglar and the previous attempts to get an insulin approved in the EU, this is not an easy task. However, it can be expected that more BioIns will come to the markets over the next years, that is, a number of different insulin glargines, but also BioIns of rapid-acting insulin analogs. Nevertheless, it is of note that a large pharmaceutical company like Pfizer has stepped back from codeveloping a BioIns with an Indian company after being in cooperation with them for a while. As with the reduction in price seen when biosimilars of other drugs outside diabetes care came to the market, the expectation is that the market introduction of these BioIns will also have an impact on the price of insulin. The question is, will insulin costs decline in the next years to a similar extent as with other biosimilars or even to an extent as was observed with generic drugs? Or in other words, what savings are to be expected wit Continue reading >>

India Is Home To Largest 'diabetes' Drugs Market Worldwide

India Is Home To Largest 'diabetes' Drugs Market Worldwide

Diabetes has been termed the 'Mother of all Diseases' and sadly despite of tremendous research by the medical industry, a permanent solution for it is yet to be found The Diabetes drug market is soon estimated to reach $55.3 billion by 2017 with foreign drum makers eyeing at India's growing diabetic population. Time to take a deep look at why drug companies are betting big on 'pharmerging' countries? PM Modi showed a lot of concern on the eve of International Yoga Day and urged yoga teachers to focus on reducing the number of diabetic patients in the India. It is time to contemplate his insistence over the issue and analyze the questions India is facing at the moment. With the world's largest population of diabetics, India is set to see the launch of a range of novel diabetes treatments from foreign drug makers such as Pfizer, Eli Lilly and Merck. Diabetes has been termed the 'Mother of all Diseases' and sadly despite of tremendous research by the medical industry, a permanent solution for it is yet to be found. Even the best medicines can only control diabetes for the time being while the dosage keeps increasing as time progresses. However, it is said the yoga can help maintaining almost all of the bodily functions at the optimum level and diabetes can be controlled by it as well. Many postures and breathing exercises in yoga have known to be inducing the pancreas to produce enough insulin and regulate the blood sugar. But drug companies have been pitching innovative delivery systems, convenience and touch technology, to expand their consumer base in large markets like India. Multinational pharmaceuticals are planning to capture a market of 32 million to 57.2 million people by 2025. Pfizer, GlaxoSmithKline, Merck, Eli Lilly, Novartis, AstraZeneca, Sanofi all wish to ha Continue reading >>

India Becomes 4th Largest Market For Sony

India Becomes 4th Largest Market For Sony

Japanese consumer electronics giant Sony on Wednesday said its Indian operations have emerged as its fourth largest globally, overtaking businesses in Brazil and Russia by the end of December quarter this fiscal. The sluggish demand in developed nations has helped the company’s growing subsidiary Sony India, which has clocked a revenue of over Rs 6,000 crore during April-December period in 2012-13, to improve its position in global ranking. “The Indian operations has become the number four in global ranking. We have overtaken Brazil and Russia, which were ahead of us in last fiscal,” Sony India Managing Director Kenichiro Hibi told reporters in Las Vegas. The existing top three positions are held by the US, China and Japan, he said without sharing details. “We have almost touched last year’s revenue... We are completely on our track to treble our turnover to Rs 20,000 crore by 2015,” Mr. Hibi said. The Indian operations’ revenue for 2011-12 was Rs 6,313 crore compared to Rs 5,446 crore in the previous fiscal. The company is expecting 30-40 per cent growth in this fiscal. Sony India’s achievement comes at a time when its parent is reporting losses due to unfavourable foreign exchange rates, impact of tsunami in Japan, floods in Thailand and adverse market sentiments in developed countries. Sony Corporation reported 9.58 per cent fall in its sales for the year ending March 31, 2012, at 6.49 trillion yen. Its net loss also widened to 456.7 billion yen in the year. For the quarter ending September 30 last year, the Japanese major incurred a net loss of 15.5 billion yen. Its sales stood at 1,604.7 billion yen. Asked about the growth driver for Sony India, Mr. Hibi said: “Bravia, Vaio and Xperia are the major contributor to our rise. These three have contrib Continue reading >>

Welcome Afrezza – Inhaled Insulin Gets Real!

Welcome Afrezza – Inhaled Insulin Gets Real!

Take a deep breath, Friends: the world’s first (seemingly) commercially viable inhalable insulin product is here. Today, Sanofi has officially launched MannKind’s long-awaited Afrezza, and we hear the product is already appearing in some pharmacies nationwide. Housed in a tiny, handy inhaler device, Afrezza is said to bring not only convenience, but also some new medical benefits to the world of rapid-acting insulin. “I don’t know if it’s gonna be a blockbuster, but I do think it’s gonna have a niche,” says Dr. Steve Edelman of UC San Diego and TCOYD (a type 1 himself), who was one of the lead investigators on Afrezza clinical trials. “I can say it has been shown in clinical trials to reduce hypoglycemia, but FDA won’t let (Sanofi) put that in the labeling. I was at the FDA public hearing in Washington, DC, and they spent all the time trying to refute the data instead of trying to understand it… It’s just a total shame FDA didn’t allow them to put that benefit in the label.” “Afrezza really does work extremely well. I can see myself taking it for incidental hypers where subcutaneous insulin is way too slow and stays around in your system way too long,” he adds. Whoa… aside from the obviously enormously superior design of the inhaler device itself over the previous Exubera fiasco, we’ve been skeptical about the practicality of Afrezza. After all, it’s just for prandial dosing, so even most type 2s would need a shot a day of long-acting insulin to complete their therapy, right? And how precise can inhaled dosing possibly be? Plus, it’s hard to get your head around how this stuff reduces hypoglycemia. Last not least, there are the issues of pricing and insurance reimbursement. Read on… and please don’t miss the product Q&A at the e Continue reading >>

Statistics And Market Analysis Of Insulin Market In India - Powerpoint Ppt Presentation

Statistics And Market Analysis Of Insulin Market In India - Powerpoint Ppt Presentation

Global Diabetes Disposable Insulin Pen Market Report: Country Outlook, Analysis, Size, Share and Forecast 2017 – 2022 - DPI Research published a latest report titled"Global Diabetes Disposable Insulin Pen Market Report: Country Outlook, Analysis, Size, Share and Forecast 2017 – 2022" to its databases Buy Now: Diabetes Disposable Insulin Pen Market is likely to reach more than US$ 9Billion across the ten major markets (10MM) of the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China, India and Brazil by the year end of 2022. Market growth can be attributed to factors such as growing diabetes patient population, high adoption rate, user–friendly design, rising popularity among consumers, help avoid over/under–dosing of insulin, rising market demand for human insulin analogs, government support and technological advancements in the field of insulin pen devices. | PowerPoint PPT presentation | free to view Continue reading >>

Lupin And Eli Lilly Expand Partnership In India

Lupin And Eli Lilly Expand Partnership In India

HOME > MEDIA > PRESS RELEASES Lupin to market Lilly’s rapid-acting Insulin analog Lispro under the brand name Eglucent® According to the agreement, Lupin will market and sell Eglucent® through its own specialty field force while Lilly will be responsible for manufacturing and import. Lilly will continue to sell Lispro under the brand name Humalog® through its existing channels. Lupin had earlier collaborated with Lilly (July, 2011) to promote and distribute Lilly’s Huminsulin range of products in India and Nepal. Eglucent® is indicated for the treatment of patients with diabetes mellitus. It is an injectable medication designed to improve blood sugar control in patients with type 1 and 2 diabetes. Eglucent® will be available in the Indian market in both, the cartridge and disposable pen form. Eglucent® is a prescription drug that should be taken only when prescribed by a registered physician. It is intended as an adjunct to diet and exercise to improve the glycemic control. Lupin is the 5th largest company in the Anti-Diabetes segment with a market share of 6.34% growing at 18% (IMS MAT September 2016). Lupin also has the distinction of being the only company in the Anti-Diabetes market with a contemporary portfolio comprising of oral anti-diabetes drugs (OAD) and injectable drugs like conventional and analog insulins. Lupin’s anti-diabetic portfolio contributes 16% to its India formulations sales (FY 2016). The Indian diabetes market is valued at INR 9,272 crore and is growing at 19% (IMS MAT September 2016). The total insulin market is valued at INR 2,207 crore, out of which the insulin analogue market size is valued at INR 1,106 crore with a 3 year CAGR of 28% (IMS MAT September 2016). The total insulin Lispro molecule market size is INR 142 crore with a Continue reading >>

Asia Pacific (india, China, Australia, South Korea & Others) Insulin Market (rapid Acting, Short Acting, Pre-mixed, Long Acting, Type I & Ii Diabetes, Analogs & Recombinant Insulin) Analysis And Segment Forecasts To 2020

Asia Pacific (india, China, Australia, South Korea & Others) Insulin Market (rapid Acting, Short Acting, Pre-mixed, Long Acting, Type I & Ii Diabetes, Analogs & Recombinant Insulin) Analysis And Segment Forecasts To 2020

Industry Insights Insulin is a hormone which facilitates the entry of glucose into the blood cells. The body’s inability to produce appropriate amount of insulin leads to accumulation of sugar in the blood stream leading to a rise in blood sugar levels and eventually diabetes. Growing global prevalence of diabetes and the increasing incidence rates of lifestyle induced disorders such as obesity are expected to drive market growth over the next six years. Insulin caters to the diabetic patient population. According to the estimates of International Diabetes Federation, the global prevalence of diabetes is expected to increase from 366 million in 2011 to 552 million by 2030 and such a rapid growth in prevalence is expected to have a high impact on market growth over the forecast period. Moreover, the presence of a strong product pipeline portfolio and the future commercialization of these products is expected to serve this market as a future growth opportunity. The Asia Pacific insulin market is dominated by three major companies including Novo Nordisk, Eli Lilly and Sanofi Aventis. These companies in an attempt to preserve market share engage in extensive R&D initiatives to develop novel insulin products with relatively higher efficacies. Moreover, unmet medical needs are taken into consideration while developing new products. E.g. Oramed’s ORMD-0801 - oral insulin for treating type II diabetes. The Asia Pacific insulin market was valued at USD 4,867.1 million in 2013 and is expected to grow at a CAGR of 17.6% during the forecast period. Report Coverage & Deliverables Product Insights Key product segments analyzed and estimated in this study include rapid acting analog, long acting analog, premixed insulin, premixed analog, short acting insulin and intermediate insul Continue reading >>

Sanofi Shakes Up Diabetes Market In India

Sanofi Shakes Up Diabetes Market In India

Mumbai: French drug maker Sanofi SA, a relative newcomer in India’s Rs.4,600 crore diabetes management market, is changing the rules of the game by lowering prices and localizing products for treatment of the disease in a country that has the world’s second largest population of diabetes patients, next only to China. The Paris-based pharmaceutical company in October launched a low-cost, reusable insulin pen called AllStar, priced at Rs.650. Used by patients for injecting insulin, the device is manufactured at a new facility in Gujarat, one of two such plants Sanofi has worldwide. India, which is home to 61 million diabetes patients, had been importing such devices before the introduction of the product. The imports are not only priced higher, but are less convenient for use by Indian patients, said Shashank Joshi, a senior endocrinologist and consultant at Lilavati Hospital in Mumbai. “AllStar is a real trendsetter as it is the first such device developed to fit the country’s requirement in terms of insulin stability in Indian conditions, reusability of the device by changing the cartridge, and its affordability,” said Joshi. Apart from being the first to produce an insulin device locally, Sanofi, which established an active diabetes portfolio globally in 2009, is planning insulin production in India shortly through local subsidiary Shantha Biotechnics Ltd as it seeks a greater market share. Cyrus Aibara, senior director of Sanofi’s diabetes business unit, said in an interview in October that production of insulin will begin in a year or two. “We will transfer insulin-making technology to Shantha, which produces vaccines at present, and the company is evaluating the whole process,” he said. India has about 126 large and small companies competing in the f Continue reading >>

The Market Size Of India Insulin Market In Terms Of Revenue

The Market Size Of India Insulin Market In Terms Of Revenue

The industry research publication titled ‘India Insulin Market Review to 2018 - Intensifying Strategic Alliances Between Companies’ presents a comprehensive analysis of market size by value of major types (human insulin, analog insulin, premix, rapid acting, long acting) of insulin consumed in India. The report entails the segment wise market share analysis and company profiles of major players in the insulin market in India. The future prospects and opportunities in the market have also been discussed in the report. The economic advancement of any country is paradoxical in nature. While on one hand it increases the affluence of the masses, the other side is characterized by diseases that are accompanied by passive lifestyles. From the several diseases caused by a sedentary form of life such as cardiovascular ailments, hypertension and high blood pressure, diabetes is also increasing at an alarming rate, especially in the developing countries. India was resident to nearly 61.5 million people suffering from diabetes in 2013, which is the second largest in the world after China. The prevalence of diabetes has made it the fifth largest disease in India. Diabetes in India is reaching epidemic proportions. Rapid cultural changes such as increasing urbanization, modified diet patterns and sedentary lifestyles among the young generation, have heightened the prevalence of diabetes in India. In 2013, while 61.5 million people suffered from diabetes in the country, another 30 million were in the pre-diabetes group. Medication for the diabetic population is the need of the hour since the disease is adding significantly to the mortality rate of India. In FY’2008, the revenue generated by the sales of insulin in India was estimated to be USD ~ million and reached USD ~ million Continue reading >>

India’s Lupin Launches Insulin Glargine Analogue Basugine

India’s Lupin Launches Insulin Glargine Analogue Basugine

Indian generic drugmaker Lupin has entered into a strategic distribution agreement with LG Life Sciences… To continue reading this article and to access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space you need to be logged into the site and have an active subscription or trial subscription. Please login or subscribe in order to continue reading. Claim a week's trial subscription by signing up for free today and receive our daily pharma and biotech news bulletin free of charge, forever. Continue reading >>

More in insulin